Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Revenue: 2012-2024

Historic Revenue for Theravance Biopharma (TBPH) over the last 13 years, with Dec 2024 value amounting to $64.4 million.

  • Theravance Biopharma's Revenue rose 18.51% to $20.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.3 million, marking a year-over-year increase of 27.12%. This contributed to the annual value of $64.4 million for FY2024, which is 12.12% up from last year.
  • Latest data reveals that Theravance Biopharma reported Revenue of $64.4 million as of FY2024, which was up 12.12% from $57.4 million recorded in FY2023.
  • Theravance Biopharma's Revenue's 5-year high stood at $71.9 million during FY2020, with a 5-year trough of $51.3 million in FY2022.
  • For the 3-year period, Theravance Biopharma's Revenue averaged around $57.7 million, with its median value being $57.4 million (2023).
  • As far as peak fluctuations go, Theravance Biopharma's Revenue decreased by 23.03% in 2021, and later climbed by 12.12% in 2024.
  • Yearly analysis of 5 years shows Theravance Biopharma's Revenue stood at $71.9 million in 2020, then fell by 23.03% to $55.3 million in 2021, then declined by 7.17% to $51.3 million in 2022, then climbed by 11.84% to $57.4 million in 2023, then rose by 12.12% to $64.4 million in 2024.